Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma

被引:0
作者
Rong Lin
Chao-qun Han
Wei-jun Wang
Jun Liu
Wei Qian
Zhen Ding
Xiao-hua Hou
机构
[1] Huazhong University of Science and Technology,Department of Gastroenterology, Union Hospital, Tongji Medical College
来源
Journal of Huazhong University of Science and Technology [Medical Sciences] | 2017年 / 37卷
关键词
pancreatic adenocarcinoma; survival; prognosis; lymph node ratio;
D O I
暂无
中图分类号
学科分类号
摘要
Survival after pancreatic cancer surgery is extremely unfavorable even after curative resection. Prognostic factors have been explored but remain largely undefined. The present study was to identify the role of clinical and laboratory variables in the prognostic significance of resectable pancreatic adenocarcinoma. A total of 96 patients who underwent curative resection for pancreatic cancer were included. Survival was evaluated based on complete follow-up visits and was associated with potential prognostic factors using the Kaplan-Meier method and Cox proportional hazard model survival analyses. The results showed that prognostic variables significantly reduced survival, including old age, poorly differentiated tumors, elevated tumor markers and positive lymph node metastasis (LNM). Age of older than 60 years (HR=1.83, P=0.04), LNM (HR=2.22, P=0.01), lymph node ratio (0<LNR≤0.2, HR=1.38, P=0.042; LNR>0.2, HR=1.92, P=0.017), initial CA199 (HR=4.80, P=0.004), and CEA level (HR=2.59, P=0.019) were identified as independent prognostic factors by multivariate analysis. It was concluded that LNR may be potent predictor of survival and suggests that surgeons and the pathologists should thoroughly assess lymph nodes prior to surgery.
引用
收藏
页码:612 / 620
页数:8
相关论文
共 120 条
[1]  
Siegel R(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29
[2]  
Ma J(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921
[3]  
Zou Z(2014)Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010 Sci Rep 4 6747-726
[4]  
Rahib L(2015)Perioperative therapy for surgically resectable pancreatic adenocarcinoma Hematol Oncol Clin North Am 29 717-1641
[5]  
Smith BD(2005)Surgery for pancreatic cancer: recent controversies and current practice Gastroenterology 128 1626-964
[6]  
Aizenberg R(2003)An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma J Am Coll Surg 196 954-2394
[7]  
Sun H(2014)The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer Anticancer research 34 2389-3
[8]  
Ma H(2015)Long-term survival after curative resection for pancreatic ductal adenocarcinoma-Surgical treatment Int J Surg 21 S1-268
[9]  
Hong G(2015)Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis World J Gastroenterol 21 262-1200
[10]  
Du L(2015)Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis Medicine 94 1345-1781